MKS Instruments vs Sana Biotechnology Inc — how do they compare? MKS Instruments trades at $266.89 (market cap $18.12B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: MKS Instruments is far larger — about 19.1× Sana Biotechnology Inc's market cap, and MKS Instruments pays a 0.37% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MKSI | SANA | |
|---|---|---|
Market Cap | $18.12B | $947.48M |
Sector | Technology | Health |
52-Week High | $444.80 | $5.92 |
52-Week Low | $110.60 | $2.68 |
Enterprise Value | $21.70B | $860.73M |
Dividend Yield | 0.37% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Trailing returns across standard periods
Latest headlines on both assets
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →